Form 4: ClearPoint Neuro Executive Settles Restricted Stock Units
SEC Form 4 Filing
L. Jeremy Stigall, Chief Business Officer of ClearPoint Neuro, settled restricted stock units for common stock and disposed of shares to cover tax obligations.
Summary
- On March 6, 2025, L. Jeremy Stigall, Chief Business Officer of ClearPoint Neuro, settled 17,777 restricted stock units, receiving an equivalent number of common stock shares.
- Stigall also disposed of 6,361 shares of common stock at a price of $13.19 to satisfy tax withholding obligations related to the vesting of the restricted stock units.
- Following these transactions, Stigall directly owns 59,031 shares of ClearPoint Neuro common stock and 17,778 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing an executive's stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company executives. It is a standard practice for publicly traded companies.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding executive compensation and stock ownership.
- The disposal of shares to cover tax obligations has a minor impact on the overall market supply of CLPT shares.
Key Dates
| Date | Description |
|---|---|
| 03/06/2025 | Date of transaction: settlement of restricted stock units and disposal of shares for tax obligations. |
| 03/10/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.